卡介苗疫苗市场 - 按年龄层（儿科、成人）、按应用（结核、膀胱癌）、最终用途（医院、诊所）和预测，2024 - 2032 年

由于全球结核病的高流行，2024 年至 2032 年间，全球卡介苗疫苗市场的复合年增长率将达到 5.4%。全球结核病的持续负担，特别是在发展中国家，刺激了对卡介苗疫苗的需求。

根据世界卫生组织估计，2022 年全球估计有1,060 万人感染结核病，高于2021 年的1,030 万人和2020 年的1,000 万人，标誌着到2020 年之前持续下降的趋势持续扭转。率（新病例）据估计，2020-2021 年和 2021-2022 年期间，每 10 万人的死亡率增加了 1.9%。随着越来越多的人罹患结核病，特别是在高风险地区，各国政府和卫生组织加强了免疫接种。这种对透过疫苗接种预防结核病的高度重视极大地促进了卡介苗疫苗市场的成长。

整个卡介苗疫苗产业根据年龄层、应用、最终用途和地区进行分类。

成人市场将在 2024 年至 2032 年期间获得可观的收益。成年人对卡介苗的需求受到多种因素的推动，包括结核病病例的增加以及高危险群（例如医护人员和免疫系统较弱的人群）的保护需求。此外，卡介苗疫苗在膀胱癌治疗中的潜在治疗用途也增加了成人对其的需求。人们对结核病预防和疫苗接种益处的认识的提高进一步鼓励了成人免疫接种。此外，全球旅行和移民使更多成年人接触结核病流行地区，促使接种疫苗作为预防措施。卫生组织的公共卫生措施和建议在推动成人卡介苗疫苗接种方面也发挥重要作用。

由于卡介苗疫苗在治疗非肌肉浸润性膀胱癌 (NMIBC) 方面已被证实的功效，膀胱癌细分市场可能会在 2024 年至 2032 年期间刺激卡介苗疫苗市场的应用前景。卡介苗疗法透过刺激免疫系统攻击癌细胞，显着降低癌症復发和进展的风险。临床研究和长期患者结果支持其有效性，使其成为标准治疗选择。此外，膀胱癌发生率的增加以及对具有成本效益的非手术治疗方案的需求也推动了需求。正在进行的研究和积极的临床试验结果进一步验证了 BCG 对膀胱癌的治疗效果，鼓励在医疗实践中广泛采用。

由于弱势群体结核病发病率上升以及结核病预防意识增强，到 2032 年，北美卡介苗市场的估值将保持适度。政府对免疫计划的大力支持和资助确保了疫苗的广泛供应和分发。此外，人们对卡介苗疫苗在治疗非肌肉浸润性膀胱癌中的作用的日益认识也推动了其在肿瘤学领域的应用。先进的医疗基础设施、强劲的研发活动以及严格的监管标准进一步支持市场成长。公共卫生活动和疾病预防控制中心等卫生组织的建议强调了卡介苗疫苗接种的重要性，有助于市场扩张。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

• 产业生态系统分析
• 产业影响力
  • 成长动力
    • 结核病 (TB) 发生率不断上升
    • 研发投资激增
    • 提高疫苗接种计划的认识和采用
  • 产业陷阱与挑战
    • 疫苗短缺和供应链挑战
• 成长潜力分析
• 报销场景
• 监管环境
• 技术景观
• 扩大卡介苗疫苗的应用
• 定价分析
• 波特的分析
• PESTEL分析

第 4 章：竞争格局

• 介绍
• 公司市占率分析
• 公司矩阵分析
• 主要市场参与者的竞争分析
• 竞争定位矩阵
• 战略仪表板

第 5 章：市场估计与预测：按年龄划分，2021 - 2032

• 主要趋势
• 儿科
• 成年人

第 6 章：市场估计与预测：按应用分类，2021 - 2032

• 主要趋势
• 结核
• 膀胱癌

第 7 章：市场估计与预测：按最终用途，2021 - 2032 年

• 主要趋势
• 医院
• 诊所

第 8 章：市场估计与预测：按地区划分，2021 - 2032 年

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 荷兰
  • 欧洲其他地区
• 亚太地区
  • 印度
  • 中国
  • 印尼
  • 菲律宾
  • 亚太地区其他地区
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 拉丁美洲其他地区
• 中东和非洲
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋
  • 中东和非洲其他地区

第 9 章：公司简介

• AJ Biologics Sdn Bhd
• BCG Vaccine Laboratory
• Biomed Lublin S.A.
• GSBPL
• Japan BCG Laboratory
• Merck & Co., Inc.
• Microgen
• Serum Institute of India Pvt. Ltd.
• Taj Pharmaceuticals Limited
• Zydus Group

Global BCG Vaccines Market will demonstrate 5.4% CAGR between 2024 and 2032, attributed to the high prevalence of Tuberculosis worldwide. The ongoing global burden of Tuberculosis, particularly in developing countries, fuels the demand for BCG vaccines.

According to WHO, an estimated 10.6 million people contracted TB globally in 2022, up from 10.3 million in 2021 and 10.0 million in 2020, marking a continued reversal of the previously sustained downward trend up to 2020. Similarly, the Tuberculosis incidence rate (new cases per 100,000 population per year) is assessed to have risen by 1.9% between 2020-2021 and 2021-2022. As more people fall ill with TB, especially in high-risk regions, governments and health organizations intensify immunization efforts. This heightened focus on TB prevention through vaccination significantly contributes to the growth of the BCG vaccines market.

The overall BCG vaccines industry is segregated based on age group, application, end-use, and region.

The adults segment will garner appreciable gains throughout 2024-2032. The demand for BCG vaccines among adults is favored by several factors, including the rise in TB cases and the need for protection in high-risk populations, such as healthcare workers and those with weakened immune systems. In addition, the BCG vaccine's potential therapeutic use in bladder cancer treatment has increased its demand among adults. Heightened awareness about TB prevention and the benefits of vaccination further encourage adult immunization. Moreover, global travel and migration expose more adults to TB-endemic regions, prompting vaccination as a preventive measure. Public health initiatives and recommendations by health organizations also play a significant role in driving adult BCG vaccination.

The bladder cancer segment could stimulate the application landscape of the BCG vaccines market over 2024-2032, propelled by the proven efficacy of BCG vaccines in treating non-muscle invasive bladder cancer (NMIBC). BCG therapy significantly reduces the risk of cancer recurrence and progression by stimulating the immune system to attack cancer cells. Clinical studies and long-term patient outcomes support its effectiveness, making it a standard treatment option. Additionally, increasing bladder cancer incidence rates and the need for cost-effective, non-surgical treatment options drive demand. Ongoing research and positive clinical trial results further validate BCG's therapeutic benefits in bladder cancer, encouraging widespread adoption in medical practice.

North America BCG vaccines market will amass a modest valuation by 2032 due to the rising incidence of Tuberculosis among vulnerable populations and increased awareness of TB prevention. Strong government support and funding for immunization programs ensure widespread vaccine availability and distribution. Additionally, the growing recognition of BCG vaccines' role in treating non-muscle invasive bladder cancer drives their adoption in oncology. Advanced healthcare infrastructure, robust research and development activities, and stringent regulatory standards further support market growth. Public health campaigns and recommendations from health organizations like the CDC reinforce the importance of BCG vaccination, contributing to the market expansion.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Growing incidence of tuberculosis (TB)
    • 3.2.1.2 Surge in R&D investments
    • 3.2.1.3 Rising awareness and adoption of vaccination programs
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Vaccine shortages and supply chain challenges
• 3.3 Growth potential analysis
• 3.4 Reimbursement scenario
• 3.5 Regulatory landscape
• 3.6 Technological landscape
• 3.7 Expanding applications of BCG vaccines
• 3.8 Pricing analysis
• 3.9 Porter's analysis
• 3.10 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Age Group, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Pediatrics
• 5.3 Adults

Chapter 6 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Tuberculosis
• 6.3 Bladder cancer

Chapter 7 Market Estimates and Forecast, By End-use, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Hospitals
• 7.3 Clinics

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
  • 8.3.7 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 India
  • 8.4.2 China
  • 8.4.3 Indonesia
  • 8.4.4 Philippines
  • 8.4.5 Rest of Asia Pacific
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
  • 8.5.4 Rest of Latin America
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE
  • 8.6.4 Rest of Middle East and Africa

Chapter 9 Company Profiles

• 9.1 AJ Biologics Sdn Bhd
• 9.2 BCG Vaccine Laboratory
• 9.3 Biomed Lublin S.A.
• 9.4 GSBPL
• 9.5 Japan BCG Laboratory
• 9.6 Merck & Co., Inc.
• 9.7 Microgen
• 9.8 Serum Institute of India Pvt. Ltd.
• 9.9 Taj Pharmaceuticals Limited
• 9.10 Zydus Group